Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

NCT00623402 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Sorafenib
DRUG: pegylated interferon α-2b

Sponsor

University Hospital Schleswig-Holstein

Collaborators

[object Object]